Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole.
Treatment-resistant depression (TRD) is a heterogeneous condition in which symptoms such as anhedonia, rumination, and anxiety contribute to persistent disability. Esketamine nasal spray (ESK-NS), accelerated repetitive transcranial magnetic stimulation (arTMS), and adjunctive brexpiprazole represent novel therapeutic options with distinct mechanisms, though their domain-specific effects in real-world settings remain unclear.
To compare short-term changes in depressive severity across ESK-NS, arTMS, and brexpiprazole, and to explore treatment-related effects on anhedonia, rumination, anxiety, and item-level depressive symptoms.
One hundred and one individuals with TRD were enrolled in a prospective, naturalistic, three-arm study and treated with ESK-NS, arTMS (accelerated left DLPFC protocol), or brexpiprazole augmentation (1-2 mg/day). Assessments were conducted at baseline and after one month.
All treatments produced significant reductions in overall depressive severity and anhedonia. Rumination showed a significant time-by-treatment interaction, with greater improvement under brexpiprazole. Item-level analyses suggested partially distinct profiles, with brexpiprazole preferentially improving pessimistic and ruminative symptoms, ESK-NS enhancing affective responsiveness and cognitive symptoms, and both ESK-NS and arTMS contributing to anxiolysis.
In routine clinical practice, ESK-NS, arTMS, and brexpiprazole were associated with short-term improvement in TRD, with exploratory signals of partially distinct symptom-domain profiles. These findings support the value of dimensional assessment in TRD and warrant confirmation in randomized studies with longer follow-up.
To compare short-term changes in depressive severity across ESK-NS, arTMS, and brexpiprazole, and to explore treatment-related effects on anhedonia, rumination, anxiety, and item-level depressive symptoms.
One hundred and one individuals with TRD were enrolled in a prospective, naturalistic, three-arm study and treated with ESK-NS, arTMS (accelerated left DLPFC protocol), or brexpiprazole augmentation (1-2 mg/day). Assessments were conducted at baseline and after one month.
All treatments produced significant reductions in overall depressive severity and anhedonia. Rumination showed a significant time-by-treatment interaction, with greater improvement under brexpiprazole. Item-level analyses suggested partially distinct profiles, with brexpiprazole preferentially improving pessimistic and ruminative symptoms, ESK-NS enhancing affective responsiveness and cognitive symptoms, and both ESK-NS and arTMS contributing to anxiolysis.
In routine clinical practice, ESK-NS, arTMS, and brexpiprazole were associated with short-term improvement in TRD, with exploratory signals of partially distinct symptom-domain profiles. These findings support the value of dimensional assessment in TRD and warrant confirmation in randomized studies with longer follow-up.
Authors
d'Andrea d'Andrea, Cavallotto Cavallotto, Susini Susini, Marsico Marsico, Mammarella Mammarella, Tamagnini Tamagnini, Inserra Inserra, Mancusi Mancusi, Di Lorenzo Di Lorenzo, Barlattani Barlattani, Pacitti Pacitti, Pettorruso Pettorruso, Martinotti Martinotti
View on Pubmed